Matches in UGent Biblio for { <https://biblio.ugent.be/publication/849985#aggregation> ?p ?o. }
Showing items 1 to 67 of
67
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B328760.
- aggregation creator B328761.
- aggregation creator B328762.
- aggregation creator B328763.
- aggregation creator B328764.
- aggregation creator B328765.
- aggregation creator B328766.
- aggregation creator B328767.
- aggregation creator B328768.
- aggregation creator B328769.
- aggregation creator B328770.
- aggregation creator B328771.
- aggregation creator B328772.
- aggregation creator B328773.
- aggregation creator B328774.
- aggregation creator B328775.
- aggregation creator B328776.
- aggregation creator B328777.
- aggregation creator B328778.
- aggregation creator B328779.
- aggregation creator B328780.
- aggregation creator B328781.
- aggregation creator B328782.
- aggregation creator B328783.
- aggregation creator B328784.
- aggregation creator B328785.
- aggregation creator B328786.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2009".
- aggregation format "application/pdf".
- aggregation hasFormat 849985.bibtex.
- aggregation hasFormat 849985.csv.
- aggregation hasFormat 849985.dc.
- aggregation hasFormat 849985.didl.
- aggregation hasFormat 849985.doc.
- aggregation hasFormat 849985.json.
- aggregation hasFormat 849985.mets.
- aggregation hasFormat 849985.mods.
- aggregation hasFormat 849985.rdf.
- aggregation hasFormat 849985.ris.
- aggregation hasFormat 849985.txt.
- aggregation hasFormat 849985.xls.
- aggregation hasFormat 849985.yaml.
- aggregation isPartOf urn:issn:1470-2045.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study".
- aggregation abstract "Background More accurate prognostic assessment of patients with neuroblastoma is required to better inform the choice of risk-related therapy. The aim of this study is to develop and validate a gene-expression signature to improve outcome prediction. Methods 59 genes were selected using an innovative data-mining strategy, and were profiled in the largest neuroblastoma patient series (n=579) to date using real-time quantitative PCR starting from only 20 ng of RNA. A multigene-expression signature was built using 30 training samples, tested on 313 test samples, and subsequently validated in a blind study on an independent set of 236 tumours. Findings The signature has a performance, sensitivity, and specificity of 85.4% (95% CI 77.7-93.2), 84.4% (66.5-94.1), and 86.5% (81.1-90.6), respectively, to predict patient outcome. Multivariate analysis indicates that the signature is a significant independent predictor of overall survival and progression-free survival after controlling for currently used risk factors: patients with high molecular risk have a higher risk of death from disease and higher risk of relapse or progression than patients with low molecular risk (odds ratio 19.32 [95% CI 6.50-57.43] and 3.96 [1.97-7.97] for overall survival and progression-free survival, respectively, both p<0.0001). Patients at an increased risk of an adverse outcome can also be identified in the current treatment groups, showing the potential of this signature for improved clinical management. These results were confirmed in the validation study, in which the signature was also independently statistically significant in a model adjusted for MYCN status, age, International Neuroblastoma Staging System stage, ploidy, International Neuroblastoma Pathology Classification grade of differentiation, and mitosis karyorrhexis index (odds ratios between 4.81 and 10.53 depending on the model for overall survival and 3.68 [95% CI 2.01-6.71] for progression-free survival). Interpretation The 59-gene expression signature is an accurate predictor of outcome in patients with neuroblastoma. The signature is an independent risk predictor, identifying patients with an increased risk of poor outcome in the current clinical-risk groups. The method and signature is suitable for routine laboratory testing, and should be evaluated in prospective studies. Funding The Belgian Foundation Against Cancer, the Children Cancer Fund Ghent, the Belgian Society of Paediatric Haematology and Oncology, the Belgian Kid's Fund and the Fondation Nuovo-Soldati (JV), the Fund for Scientific Research Flanders (KDP, JH), the Fund for Scientific Research Flanders, the institute for the Promotion of Innovation by Science and Technology in Flanders, Strategisch basisonderzoek, the Fondation Fournier Majoie pour l'Innovation, the Instituto Carlos III, the Italian Neuroblastoma Foundation, the European Community under the FP6, and the Belgian programme of Interuniversity Poles of Attraction.".
- aggregation authorList BK620081.
- aggregation endPage "671".
- aggregation issue "7".
- aggregation startPage "663".
- aggregation volume "10".
- aggregation aggregates 863988.
- aggregation isDescribedBy 849985.
- aggregation similarTo S1470-2045(09)70154-8.
- aggregation similarTo LU-849985.